Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to prove the superiority of concurrent chemoradiation compared with radiotherapy alone in patients with low risk NK/T-cell lymphoma.


Clinical Trial Description

Radiotherapy alone is commonly used in NK/T-cell lymphoma without adverse risk including lymph node involvement, local invasion, B symptoms and high LDH level. Recently, methotrexate was prove to be a radiosensitizer in NK/T-cell lymphoma cells. Therefore, the investigators aim to verify the superiority and safety of weekly methotrexate in combination with radiotherapy in a randomized phase II study. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01667289
Study type Interventional
Source Fudan University
Contact
Status Terminated
Phase Phase 2
Start date June 2012
Completion date June 2017

See also
  Status Clinical Trial Phase
Terminated NCT04509466 - Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL Phase 1/Phase 2
Not yet recruiting NCT04676789 - Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL Phase 2
Active, not recruiting NCT01991158 - GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma Phase 2
Active, not recruiting NCT03363555 - SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma Phase 2
Recruiting NCT04405375 - GPED Regimen for Relapsed/Refractory or Advanced ENKTCL Phase 2
Recruiting NCT02742727 - CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Phase 1/Phase 2
Active, not recruiting NCT02631239 - MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma Phase 3
Recruiting NCT01667302 - Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma Phase 2
Not yet recruiting NCT04338282 - Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma Phase 2
Active, not recruiting NCT04414163 - A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type Phase 2
Recruiting NCT05978141 - A Registry for People With T-cell Lymphoma
Completed NCT02386813 - International Extranodal NK/T-cell Lymphoma Project N/A
Recruiting NCT01921790 - Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma Phase 2
Completed NCT03493451 - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Phase 2